Hydroxy cycloalkyl fused pyridone carboxylic acid M(1) positive allosteric modulators.

[1]  M. Seager,et al.  N-heterocyclic derived M1 positive allosteric modulators. , 2010, Bioorganic & medicinal chemistry letters.

[2]  M. Seager,et al.  Pyridine containing M(1) positive allosteric modulators with reduced plasma protein binding. , 2010, Bioorganic & medicinal chemistry letters.

[3]  M. Quirk,et al.  A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.

[4]  Craig W. Lindsley,et al.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.

[5]  C. Lindsley,et al.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. , 2009, Trends in pharmacological sciences.

[6]  A. Deutch,et al.  Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.

[7]  Christopher J Langmead,et al.  Muscarinic acetylcholine receptors as CNS drug targets. , 2008, Pharmacology & therapeutics.

[8]  C. Strader,et al.  Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. , 2001, Farmaco.

[9]  Changiz Geula,et al.  Abnormalities of neural circuitry in Alzheimer's disease , 1998, Neurology.

[10]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[11]  A. Levey.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Bonner.  The molecular basis of muscarinic receptor diversity , 1989, Trends in Neurosciences.

[13]  H. Agui,et al.  Studies on quinoline derivatives and related compounds. III. A novel pyridine synthesis to give substituted 1,4-dihydro-4-oxonicotinic acids† , 1975 .

[14]  R. Gould,et al.  The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines , 1939 .

[15]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.